157 related articles for article (PubMed ID: 3026971)
1. HTLV-III infection of EBV-genome-positive B-lymphoid cells with or without detectable T4 antigens.
Salahuddin SZ; Ablashi DV; Hunter EA; Gonda MA; Sturzenegger S; Markham PD; Gallo RC
Int J Cancer; 1987 Feb; 39(2):198-202. PubMed ID: 3026971
[TBL] [Abstract][Full Text] [Related]
2. Complementation between infecting Epstein-Barr virus and intrinsic viral genomes in human lymphoid cell lines.
Lidin BI; Lamon EW; Cloud G; Soong SJ
Intervirology; 1982; 18(1-2):66-75. PubMed ID: 6288617
[TBL] [Abstract][Full Text] [Related]
3. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
McDougal JS; Mawle A; Cort SP; Nicholson JK; Cross GD; Scheppler-Campbell JA; Hicks D; Sligh J
J Immunol; 1985 Nov; 135(5):3151-62. PubMed ID: 2995487
[TBL] [Abstract][Full Text] [Related]
4. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
5. Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.
Klein G; Sugden B; Leibold W; Menezes J
Intervirology; 1974; 3(4):232-44. PubMed ID: 4376804
[TBL] [Abstract][Full Text] [Related]
6. Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody.
Slovin SF; Frisman DM; Tsoukas CD; Royston I; Baird SM; Wormsley SB; Carson DA; Vaughan JH
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2649-53. PubMed ID: 6283539
[TBL] [Abstract][Full Text] [Related]
7. Lymphotropic viruses, Epstein-Barr virus (EBV) and human T-cell lymphotropic virus-I (HTLV-I)/adult T-cell leukemia virus (ATLV), and HTLV-III/human immune deficiency virus (HIV) as etiological agents of malignant lymphoma and immune deficiency.
Purtilo DT
AIDS Res; 1986 Dec; 2 Suppl 1():S1-6. PubMed ID: 2881552
[TBL] [Abstract][Full Text] [Related]
8. Effects of DNA synthesis inhibitors on early antigen expression following primary infection or superinfection by Epstein-Barr virus.
Lidin BI; Lamon EW
Arch Virol; 1983; 77(1):13-25. PubMed ID: 6312934
[TBL] [Abstract][Full Text] [Related]
9. Induction of Epstein-Barr virus in B-lymphoblastoid cells by human immunodeficiency virus type 1.
Lai PK; Li X; Volsky DJ
Int J Cancer; 1989 Jun; 43(6):1104-11. PubMed ID: 2543643
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus antibodies in patients with ataxia-telangiectasia and other immunodeficiency diseases.
Joncas JH; Wills A; Reece E; Fox Z
Can Med Assoc J; 1981 Oct; 125(8):845-9. PubMed ID: 6272957
[TBL] [Abstract][Full Text] [Related]
11. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D
Intervirology; 1975; 5(6):319-34. PubMed ID: 181343
[TBL] [Abstract][Full Text] [Related]
12. Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.
Pahwa S; Pahwa R; Saxinger C; Gallo RC; Good RA
Proc Natl Acad Sci U S A; 1985 Dec; 82(23):8198-202. PubMed ID: 2999797
[TBL] [Abstract][Full Text] [Related]
13. [Variants of the interaction of the human T-cell leukemia virus (HTLV-I) with the B-cells of lymphoblastoid lines].
Iakovleva LS; Pavlish OA; Tupitsin NN; Gurtsevich VE
Vopr Virusol; 1992; 37(5-6):232-5. PubMed ID: 1337802
[TBL] [Abstract][Full Text] [Related]
14. [Epstein-Barr virus-specific immunity in asymptomatic carriers of human T-cell leukemia virus type 1].
Kwon KW
Hokkaido Igaku Zasshi; 1995 Mar; 70(2):315-28. PubMed ID: 7774883
[TBL] [Abstract][Full Text] [Related]
15. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.
Ruscetti FW; Mikovits JA; Kalyanaraman VS; Overton R; Stevenson H; Stromberg K; Herberman RB; Farrar WL; Ortaldo JR
J Immunol; 1986 May; 136(10):3619-24. PubMed ID: 2422259
[TBL] [Abstract][Full Text] [Related]
16. Productive Epstein-Barr viral infection of the human lymphoblastoid cell line 6410 with release of early antigen inducing and transforming virus.
Traul KA; Stephens R; Gerber P; Peterson WD
Int J Cancer; 1977 Aug; 20(2):247-55. PubMed ID: 197026
[TBL] [Abstract][Full Text] [Related]
17. Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-I.
De Rossi A; Franchini G; Aldovini A; Del Mistro A; Chieco-Bianchi L; Gallo RC; Wong-Staal F
Proc Natl Acad Sci U S A; 1986 Jun; 83(12):4297-301. PubMed ID: 2424024
[TBL] [Abstract][Full Text] [Related]
18. Infection of leukaemic B lymphocytes by Epstein Barr virus.
Doyle MG; Catovsky D; Crawford DH
Leukemia; 1993 Nov; 7(11):1858-64. PubMed ID: 8231253
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
Konttinen YT; Bluestein HG; Zvaifler NJ
J Immunol; 1985 Apr; 134(4):2287-93. PubMed ID: 2857749
[TBL] [Abstract][Full Text] [Related]
20. Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells.
Doyle MG; Crawford DH
Intervirology; 1994; 37(5):236-44. PubMed ID: 7698878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
